Outcome of coronary revascularisation in diabetes

Netherlands Journal of Medicine

Volumn 64, Issue 8, 2006, Pages 265-266

  Smits, P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; INSULIN; METFORMIN; SULFONYLUREA;

ACUTE HEART INFARCTION; ANGIOPLASTY; CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; DYSLIPIDEMIA; EDITORIAL; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; INTERMETHOD COMPARISON; ISCHEMIC PRECONDITIONING; MORTALITY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REPERFUSION INJURY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33749057321     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Timmer JR, Breeman A, Ottervanger JP, de Kluiver EP, Boonstra PW, Zijlstra F. Long-term clinical outcome of patients with diabetes proposed for coronary revasularisation. Neth J Med 2006;64:296-301.
2. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2006;293;1501-8.
3. Goldberg IJ, Dansky HM. Diabetic vascular disease. An experimental objective. Arterioscler Thromb Vasc Biol 2006;26:1693-701.
4. Natham DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
5. Hearse DJ, Stewart DA, Chain EB. Diabetes and the survival and recovery of the anoxic myocardium. J Mol Cell Cardiol 1975;7:397-415.
6. Riksen NP, Smits P, Rongen GA. Ischaemic preconditioning: from molecular characterisation to clinical application-part II. Neth J Med 2004;62:409-23.
7. ATP channel function in the fetoplacental circulation of patients with type 1 diabetes mellitus. Am J Obstet Gynecol 2005;192:973-9.
8. Riksen NP, Smits P, Rongen GA. Ischaemic preconditioning: from molecular characterisation to clinical application-part I. Neth J Med 2004;62:353-63.
9. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
10. Bijlstra PJ, den Arend JA, Lutterman JA, Russel FG, Thien T, Smits P. Blockade of vascular ATP-sensitive potassium channels reduces the vasodilator response to ischaemia in humans. Diabetologia 1996;39:1562-8.
11. ATP channel activation induces ischemic preconditioning of the endothelium in humans in vivo. Circulation 2004;110:2077-82.
12. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531-7.
13. Garrat KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24.
14. Legtenberg RJ, Houston RJ, Oeseburg B, Smits P. Metformin improves cardiac functional recovery after ischemia in rats. Horm Metab Res 2002;34:182-5.
15. Legtenberg RJ, Houston RJ, Oeseburg B, Smits P. Physiological insulin concentrations protect against ischemia-induced loss of cardiac function in rats. Comp Biochem Physiol A Mol Integr Physiol 2002;132:161-7.
16. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002;51:1507-14.